Patheon N.V. Initial Public Offering

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $719 million initial public offering by Patheon N.V. (“Patheon”). The IPO comprised a primary offering of 29,464,286 ordinary shares, including 4,464,286 ordinary shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, and a secondary offering of 4,761,905 ordinary shares by Koninklijke DSM N.V. The ordinary shares are listed on the New York Stock Exchange under the symbol “PTHN.”

Patheon is a leading global provider of pharmaceutical development and manufacturing services. With approximately 8,000 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. Patheon N.V. is a Dutch limited liability company (naamloze vennootschap), and Patheon’s U.S. headquarters is in Durham, North Carolina.

The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Shane Tintle and associates Dan Gibbons and Win Rutherfurd. The tax team included partner Kathleen L. Ferrell and associates Dao Fu and Veronica Orecharova. Partner Frank J. Azzopardi provided intellectual property and technology advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the New York and London offices.